Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 901-910 of 2489 for cancer

Edit search filters
  1. Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

    Rochester, MN

  2. Taletrectinib Phase 2 Global Study In ROS1 Positive NSCLC

    Rochester, MN

  3. Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

    Rochester, MN

  4. Study to Evaluate the Safety, Tolerability and Preliminary Antitumor Activity of INCB059872 in Patients with Relapsed/Refractory Ewing Sarcoma

    Jacksonville, FL

  5. Study Of ORIC-533 In Relapsed Or Refractory Multiple Myeloma

    Rochester, MN

  6. Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer

    Rochester, MN

  7. A Study to Evaluate Abemaciclib to Treat Advanced Bone and Soft Tissue Sarcoma Identified as Having CDK Pathway Alteration

    Jacksonville, FL

  8. Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia

    Rochester, MN

  9. Study to Investigate the Safety and Effectiveness of Two Doses of the Antibody Drug GSK2857916 in Relapsed/Refractory Multiple Myeloma Patients

    Rochester, MN

  10. Ixazomib Citrate In Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory To Bortezomib

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

.

Mayo Clinic Footer